Health Trials

Replication Repair Deficient

2

Review clinical trials related to Replication Repair Deficient. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

The goal of this study is to further evaluate feasibility and tolerability of Opdualag for patients with replication repair deficient HGG, including DIPG.

Participants needed: 12
Trial details
Phase: Phase 2Age: 12-39Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Jun 12, 2026
Eligibility criteria

Patients must be ≥12 years and ≤39 years of age at the time of enrollment on Tar... [+29]

Pregnant or breastfeeding patients are excluded. [+18]

Read more
Status: Recruiting

A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)

This is open label, multicentre, single arm, pilot study of upfront nivolumab in patients with RRD-glioblastoma with favorable immune/genomic biomarkers. The purpose of the study is to use upfront immune checkpoint inhibitor (ICI) to delay/avoid radiation for patients with RRD-glioblastoma with favorable clinical (Gross total resection (GTR) or near total resection (NTR)) and biological (RRD, hypermutation, immune activation) biomarkers. At progression, patients will be undergoing surgery/biopsy and will get a combination of radiation + ICI followed by maintenance ICI. This model will allow us to additionally study the evolution tumor in response to ICI. The study will have two domains.

Participants needed: 20
Trial details
Age: 12-25Biological sex: AllType: InterventionalSponsor: Daniel MorgensternUpdated: Aug 29, 2025Locations: 1
Eligibility criteria

3.1.1 Age: Patients must be ≥12 months and ≤25 years of age at the time of signi... [+18]

3.2.1 [+16]

Read more